Testicular cancer: low testosterone and the metabolic syndrome

Cure rates for stage 1 testicular cancer are reaching 100%. However, long ‐term treatment‐related side effects pose their own health risks. Regular follow up and monitoring are important for early detection and timely treatment of conditions such as testosterone deficiency and metabolic syndrome.
Source: Trends in Urology and Men's Health - Category: Urology & Nephrology Authors: Tags: Oncology Source Type: research

Related Links:

Publication date: Available online 26 May 2020Source: Molecular and Cellular ProbesAuthor(s): Jieping Hu, Jun Deng, Runfu Cao, Shida Xiong, Ju Guo
Source: Molecular and Cellular Probes - Category: Molecular Biology Source Type: research
Publication date: Available online 27 May 2020Source: Life SciencesAuthor(s): Mengwei Wu, Xiaodong Tan, Peng Liu, Yifan Yang, Yinpeng Huang, Xinlu Liu, Xiangli Meng, Boqiang Yu, Yunhao Wu, Haoyi Jin
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 26 May 2020Source: Life SciencesAuthor(s): Delu Dong, Yuan Dong, Jiaying Fu, Shengyao Lu, Chunli Yuan, Meihui Xia, Liankun Sun
Source: Life Sciences - Category: Biology Source Type: research
Autophagy is a well-maintained process by which the cells recycle intracellular materials to maintain homeostasis in various cellular functions. However, autophagy is a defensive mechanism that maintains cell survival under antagonistic conditions, the induction of the autophagic process may substantially lead to cell death. The conflicting roles of autophagy including allowing cell survival or promoting cell death could have a troublesome impact on the efficiency of chemotherapeutic agents. Accordingly, understanding the role of autophagy in cancer is a vital need for its optimal manipulation in therapy.
Source: Current Chemical Biology - Category: Biochemistry Source Type: research
In human cells, Heat Shock Protein-90 (HSP-90) is present in the cytosol, nucleoplasm, endoplasmic reticulum, and mitochondria. The eukaryotic HSP-90 is multifunctionary and essential for cell viability, signal transduction, cell-cycle control as well as transcriptional regulation. The intracellular environment does not restrict HSP-90. It has a vital role in all types of inflammatory disorders, including cancer, autoimmune diseases, infectious inflammatory conditions. Hence, pharmacological inhibition of HSP-90 is currently a choice of therapeutic target for the treatment of autoimmune diseases, cancer, and infectious dis...
Source: Current Chemical Biology - Category: Biochemistry Source Type: research
Authors: Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB, Platinum Study Group Abstract Background: Testicular cancer survivors (TCS) are at significantly increased risk for cardiovascular disease (CVD), with metabolic syndrome (MetS) an established risk factor. No study has addressed clinical and genetic MetS risk factors in North American TCS. Patients and Methods: TCS were aged
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Twenty to thirty percent of testicular cancer (TC) survivors have elevated serum levels of luteinising hormone (LH) with or without corresponding low testosterone levels (Leydig cell dysfunction) during clinical follow-up for TC. However, it remains to be clarified if this subgroup of TC survivors has an increased long-term risk of systemic inflammation and metabolic syndrome (MetS) when compared with TC survivors with normal Leydig cell function during follow-up.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
AbstractCancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary –gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the ter minal stage of a malignancy present with low testosterone concentrations as a part of anorexia–cachexia syndrome. Oncological manageme...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, testicular cancer patients with signs of hypogonadism presented with significantly increased risk of metabolic syndrome and investigation of endocrine and metabolic parameters is warranted in these patients.
Source: Andrology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Abstract BACKGROUND: Chemotherapy can affect taste and smell function. This may contribute to the high prevalence of overweight and metabolic syndrome in testicular cancer survivors (TCS). Aims of the study were to evaluate taste and smell function and possible consequences for dietary intake, food preference, and body composition in TCS treated with cisplatin-based chemotherapy. METHODS: Fifty TCS, 1-7 years post-chemotherapy, and 50 age-matched healthy men participated. Taste and smell function were measured using taste strips and 'Sniffin' Sticks', respectively. Dietary intake was investigated using a food...
Source: Appetite - Category: Nutrition Authors: Tags: Appetite Source Type: research
More News: Cancer | Cancer & Oncology | Low Testosterone | Metabolic Syndrome | Testicular Cancer | Urology & Nephrology